Literature DB >> 33047623

Which Oxford Knee Score level represents a satisfactory symptom state after undergoing a total knee replacement?

Lina H Ingelsrud1, Berend Terluin2, Kirill Gromov1, Andrew Price3, David Beard3, Anders Troelsen1.   

Abstract

Background and purpose - Meaningful interpretation of postoperative Oxford Knee Score (OKS) levels is challenging. We established Patient Acceptable Symptoms State (PASS) and Treatment Failure (TF) values for the OKS in patients undergoing primary total knee replacement (TKR) in Denmark.Patients and methods - Data from patients undergoing primary TKR between February 2015 and January 2019 was extracted from the arthroplasty registry at the Copenhagen University Hospital, Hvidovre in Denmark. Data included 3, 12, and 24 months postoperative responses to the OKS and 2 anchor questions asking whether they considered their symptom state to be satisfactory, and if not, whether they considered the treatment to have failed. PASS and TF threshold values were calculated using the adjusted predictive modeling method. Non-parametric bootstrapping was used to derive 95% confidence intervals (CI).Results - Complete 3, 12, and 24 months postoperative data was obtained for 187 of 209 (89%), 884 of 915 (97%), and 575 of 586 (98%) patients, with median ages from 68 to 70 years (59 to 64% female). 72%, 77%, and 79% considered as having satisfactory symptoms, while 6%, 11%, and 11% considered the treatment to have failed, at 3, 12, and 24 months postoperatively, respectively. OKS PASS values (CI) were 27 (26-28), 30 (29-31), and 30 (29-31) at 3, 12, and 24 months postoperatively. TF values were 27 (26-28) and 27 (26-29) at 12 and 24 months postoperatively.Interpretation - The OKS PASS values can be used to guide the interpretation of TKR outcome and support quality assessment in institutional and national registries.

Entities:  

Mesh:

Year:  2020        PMID: 33047623      PMCID: PMC7919874          DOI: 10.1080/17453674.2020.1832304

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


  17 in total

1.  Questionnaire on the perceptions of patients about total knee replacement.

Authors:  J Dawson; R Fitzpatrick; D Murray; A Carr
Journal:  J Bone Joint Surg Br       Date:  1998-01

2.  Minimal important change (MIC) based on a predictive modeling approach was more precise than MIC based on ROC analysis.

Authors:  Berend Terluin; Iris Eekhout; Caroline B Terwee; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2015-03-28       Impact factor: 6.437

Review 3.  Knee replacement.

Authors:  Andrew J Price; Abtin Alvand; Anders Troelsen; Jeffrey N Katz; Gary Hooper; Alastair Gray; Andrew Carr; David Beard
Journal:  Lancet       Date:  2018-11-03       Impact factor: 79.321

4.  Unlike ROC analysis, a new IRT method identified clinical thresholds unbiased by disease prevalence.

Authors:  Berend Terluin; Philip Griffiths; Johannes C van der Wouden; Lina Holm Ingelsrud; Caroline B Terwee
Journal:  J Clin Epidemiol       Date:  2020-05-11       Impact factor: 6.437

5.  Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state.

Authors:  F Tubach; P Ravaud; G Baron; B Falissard; I Logeart; N Bellamy; C Bombardier; D Felson; M Hochberg; D van der Heijde; M Dougados
Journal:  Ann Rheum Dis       Date:  2004-05-06       Impact factor: 19.103

6.  Treatment Success Following Joint Arthroplasty: Defining Thresholds for the Oxford Hip and Knee Scores.

Authors:  David F Hamilton; Fanny L Loth; Deborah J MacDonald; Karlmeinrad Giesinger; James T Patton; A Hamish Simpson; Colin R Howie; Johannes M Giesinger
Journal:  J Arthroplasty       Date:  2018-03-30       Impact factor: 4.757

7.  Interpretation of patient-reported outcomes for hip and knee replacement surgery: identification of thresholds associated with satisfaction with surgery.

Authors:  A Judge; N K Arden; A Kiran; A Price; M K Javaid; D Beard; D Murray; R E Field
Journal:  J Bone Joint Surg Br       Date:  2012-03

8.  What is a good patient reported outcome after total hip replacement?

Authors:  N K Arden; A Kiran; A Judge; L C Biant; M K Javaid; D W Murray; A J Carr; C Cooper; R E Field
Journal:  Osteoarthritis Cartilage       Date:  2010-10-15       Impact factor: 6.576

9.  Medial unicompartmental knee arthroplasty: increasingly uniform patient demographics despite differences in surgical volume and usage-a descriptive study of 8,501 cases from the Danish Knee Arthroplasty Registry.

Authors:  Cecilie Henkel; Mette Mikkelsen; Alma B Pedersen; Lasse E Rasmussen; Kirill Gromov; Andrew Price; Anders Troelsen
Journal:  Acta Orthop       Date:  2019-04-11       Impact factor: 3.717

10.  Patient acceptable symptom states after totalhip or knee replacement at mid-term follow-up: Thresholds of the Oxford hip and knee scores.

Authors:  J C Keurentjes; F R Van Tol; M Fiocco; C So-Osman; R Onstenk; A W M M Koopman-Van Gemert; R G Pöll; R G H H Nelissen
Journal:  Bone Joint Res       Date:  2014-01-13       Impact factor: 5.853

View more
  3 in total

1.  Comparing surgical strategies for end-stage anteromedial osteoarthritis : total versus unicompartmental knee arthroplasty.

Authors:  Mette Mikkelsen; Hannah A Wilson; Kirill Gromov; Andrew J Price; Anders Troelsen
Journal:  Bone Jt Open       Date:  2022-05

2.  Interpretation threshold values for the Oxford Knee Score in patients undergoing unicompartmental knee arthroplasty.

Authors:  Lasse K Harris; Anders Troelsen; Berend Terluin; Kirill Gromov; Andrew Price; Lina H Ingelsrud
Journal:  Acta Orthop       Date:  2022-07-05       Impact factor: 3.925

3.  Disentangling treatment pathways for knee osteoarthritis: a study protocol for the TREATright study including a prospective cohort study, a qualitative study and a cost-effectiveness study.

Authors:  Simon Majormoen Bruhn; Lina Holm Ingelsrud; Thomas Bandholm; Søren Thorgaard Skou; Henrik M Schroder; Susanne Reventlow; Anne Møller; Jakob Kjellberg; Thomas Kallemose; Anders Troelsen
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.